Market Closed -
Nasdaq
04:00:00 2024-03-28 pm EDT
5-day change
1st Jan Change
0.41
USD
-4.21%
-18.00%
-33.53%
Sales 2024 *
5.02M
Sales 2025 *
8.17M
Capitalization
6.96M
Net income 2024 *
-12M
Net income 2025 *
-13M
EV / Sales 2024 *
1.39
x
Net cash position
2024
*
-
Net cash position
2025
*
-
EV / Sales 2025 *
0.85
x P/E ratio 2024 *
-0.63
x
P/E ratio 2025 *
-0.77
x
Employees
54
Yield 2024 *
-
Yield 2025 *
-
Free-Float
87.36%
Duration
1 day 1 week 1 month 3 months 6 months 1 year 5 years 10 years
Period
5 minutes 15 minutes 30 minutes 1 hour 1 day 1 week 1 month 1 year
Style
CandleStick End-of-day OHLC Mountain
Dynamic Chart
Applied DNA Sciences, Inc. to Showcase Linea DNA and Linea IVT Platforms At 24Th Annual World Vaccine Congress
Mar. 14
CI
Applied DNA Sciences Files Prospectus for Potential Secondary Stock Offerings
Mar. 12
MT
Transcript : Applied DNA Sciences, Inc., Q1 2024 Earnings Call, Feb 08, 2024
Feb. 08
Earnings Flash (APDN) APPLIED DNA SCIENCES Reports Q1 Revenue $891,164
Feb. 08
MT
Applied DNA Sciences, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023
Feb. 08
CI
Applied DNA Sciences, Inc. Announces Joint Development Agreement to Integrate Linea IVT Platform into CDMO Kudo Biotechnology?s mRNA Manufacturing Workflow
Dec. 14
CI
HC Wainwright Cuts Price Target on Applied DNA Sciences to $2 From $4, Keeps Buy Rating
Dec. 08
MT
Transcript : Applied DNA Sciences, Inc., Q4 2023 Earnings Call, Dec 07, 2023
Dec. 07
Earnings Flash (APDN) APPLIED DNA SCIENCES Posts Q4 Revenue $779,736, vs. Street Est of $1.7M
Dec. 07
MT
Applied DNA Sciences, Inc. Reports Earnings Results for the Fourth Quarter Ended September 30, 2023
Dec. 07
CI
Applied DNA Sciences, Inc. Reports Earnings Results for the Full Year Ended September 30, 2023
Dec. 07
CI
Applied DNA Sciences, Inc. Announces Receipt of Linea(TM) DNA Follow-On Order for Cancer Diagnostic Application
Nov. 28
CI
Applied DNA Sciences, Inc. Extends Application of Linea(Tm) Ivt Platform to Sna (Self-Amplifying Mrna)
Nov. 16
CI
Applied DNA Sciences, Inc. Advances Commercialization of Linea(TM) IVT Platform
23-09-06
CI
Applied DNA Sciences, Inc. Announces Appointment of Beverly Wolgast as Executive Director of Quality and cGMP Programs
23-09-06
CI
More news
Applied DNA Sciences : informe des avancées de la collaboration avec Takis Biotech concernant le COVID-19 et de la conception de 4 candidats vaccins LinearDNA™ au stade préclinique
20-03-02
Aktuelle Meldung von Applied DNA Sciences zur COVID-19-Kooperation mit Takis Biotech: vier präklinische LinearDNA™-Impfstoffkandidaten entwickelt
20-03-02
Applied DNA Sciences : GHCL, un acteur mondial du linge de maison, crée "CIRKULARITY", une plateforme de marques inspirée par le linge de lit "REKOOP" en polyester recyclé durable et traçable
18-10-29
Applied DNA Sciences : GHCL, azienda internazionale di tessuti per la casa, crea “CIRKULARITY”, una piattaforma di marchi ispirata da “REKOOP”, biancheria in poliestere riciclato, sostenibile e tracciabile
18-10-29
Applied DNA Sciences : GHCL, weltweiter Anbieter von Heimtextilien, gründet die Markenplattform „CIRKULARITY“, inspiriert von „REKOOP“, der Lösung für nachhaltige, rückverfolgbare, recycelte Polyester-Bettwäsche
18-10-29
More news 1 day -4.21%
1 week -18.00%
Current month -29.47%
1 month -31.21%
3 months -35.94%
6 months -65.83%
Current year -33.53%
More quotes
Managers
Title Age Since
Chief Executive Officer
71
05-09-27
Director of Finance/CFO
47
13-04-30
Chief Tech/Sci/R&D Officer
-
-
Members of the board
Title Age Since
Director/Board Member
74
06-03-16
Director/Board Member
87
16-10-06
Chief Executive Officer
71
05-09-27
More insiders
Date
Price
Change
Volume
24-03-28
0.41
-4.21%
50,495
24-03-27
0.428
-1.77%
62,574
24-03-26
0.4357
-9.23%
81,413
24-03-25
0.48
-3.81%
57,984
24-03-22
0.499
-0.20%
95,784
Delayed Quote
Nasdaq, March 28, 2024 at 04:00 pm EDT
More quotes
Applied DNA Sciences, Inc. is a biotechnology company that develops, and markets deoxyribonucleic acid (DNA) based technology solutions. The Company is utilizing its LinearDNA large-scale polymerase chain reaction (PCR) based manufacturing platform. The Company's proprietary platform produces large quantities of DNA for use in the nucleic acid-based in vitro diagnostics and preclinical nucleic-acid based drug development and manufacturing markets and for supply chain security, anti-counterfeiting and anti-theft technology purposes. It also develops PCR-based molecular in vitro diagnostics for covid-19. In addition, under its wholly owned subsidiary, Applied DNA Clinical Labs, LLC, the Company is offering a high-throughput turnkey solution for population-scale Covid-19 testing marketed as safeCircle. safeCircle utilizes the Company's Covid-19 Diagnostic Tests and is designed to look for infection within defined populations or communities utilizing high throughput testing methodologies.
More about the company
Last Close Price
0.41
USD
Average target price
2.25
USD
Spread / Average Target
+448.78%
Consensus
1st Jan change
Capi.
-33.53% 7.27M -13.95% 8.1B -4.01% 5.13B -0.04% 4.72B -32.93% 4.4B +0.39% 4.14B +16.88% 2.82B +3.24% 2.55B +11.39% 1.92B +1.28% 1.65B
Diagnostic & Testing Substances
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1